Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WISTERIA: Adavosertib with Cisplatin and Radiotherapy in Head and Neck Cancer
NCT03028766Phase 1Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adavosertib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University of Birmingham. Primary endpoints: Recommended dose(s) of AZD1775 and Safety profile of AZD1775. Started Jun 2017; status: completed.
02
Drugs
adavosertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03028766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03028766.